WAVE LIFE SCIENCES LTD. Net Income (Loss) Available to Common Stockholders, Basic
WAVE LIFE SCIENCES LTD. (WVE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$204.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. net income (loss) available to common stockholders, basic for fiscal 2025 was -$204.38M.
- WAVE LIFE SCIENCES LTD. net income (loss) available to common stockholders, basic for fiscal 2024 was -$97.01M.
- WAVE LIFE SCIENCES LTD. net income (loss) available to common stockholders, basic for fiscal 2023 was -$57.51M.
- WAVE LIFE SCIENCES LTD. net income (loss) available to common stockholders, basic for fiscal 2022 was -$161.82M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$204.38M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$97.01M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$57.51M 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$161.82M 10-K · filed 2025-03-04 | |
| 2021-12-31 | -$122.25M 10-K · filed 2023-03-23 | |
| 2020-12-31 | -$149.91M 10-K · filed 2022-03-03 | |
| 2019-12-31 | -$193.64M 10-K · filed 2021-03-04 | |
| 2018-12-31 | -$146.65M 10-K · filed 2020-03-02 | |
| 2017-12-31 | -$101.98M 10-K · filed 2020-03-02 | -$102.03M 10-K · filed 2018-03-12 |
| 2016-12-31 | -$55.66M 10-K · filed 2019-03-01 | -$55.40M 10-K · filed 2017-03-16 |
| 2015-12-31 | -$19.20M 10-K · filed 2018-03-12 | |
| 2014-12-31 | -$5.23M 10-K · filed 2017-03-16 | |
| 2013-12-31 | -$3.32M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |